Summary
Johnson & Johnson's 2013 10-K filing highlights a diversified healthcare business structured across three key segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The company operates with a decentralized management approach, overseeing over 275 operating companies globally. A significant focus for investors is the substantial commitment to research and development, with R&D expenditures totaling $8.2 billion in fiscal year 2013, underscoring the company's strategy of innovation and product improvement across all segments. The filing also touches upon key product lines, including prominent brands like JOHNSON’S® Baby, AVEENO®, LISTERINE®, TYLENOL®, and prescription drugs such as REMICADE®, STELARA®, and XARELTO®. While the company emphasizes the material importance of its patents and trademarks, it acknowledges potential risks associated with patent expirations, particularly for its leading product, REMICADE®. Investors should note the company's ongoing compliance efforts with environmental and governmental regulations, which are generally not expected to have a material adverse effect.
Financial Highlights
54 data points| Revenue | $71.31B |
| Cost of Revenue | $22.34B |
| Gross Profit | $48.97B |
| SG&A Expenses | $21.83B |
| Operating Income | $16.41B |
| Interest Expense | $482.00M |
| Net Income | $13.83B |
| EPS (Basic) | $4.92 |
| EPS (Diluted) | $4.81 |
| Shares Outstanding (Basic) | 2.81B |
| Shares Outstanding (Diluted) | 2.88B |
Key Highlights
- 1Johnson & Johnson operates a globally diversified healthcare business across Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments.
- 2The company significantly invests in innovation, with R&D expenditures reaching $8.2 billion in fiscal year 2013.
- 3Key product lines include well-known consumer brands and significant pharmaceutical products like REMICADE®, STELARA®, and XARELTO®.
- 4The company acknowledges the material importance of its patent portfolio, with REMICADE® patents expiring in the coming years, a factor that could impact future sales.
- 5Operations are spread across more than 275 subsidiaries in 60 countries, indicating a broad global reach.
- 6The company's manufacturing footprint includes 144 facilities worldwide, with substantial space dedicated to each of its three business segments.
- 7Disclosure controls and procedures were deemed effective by management at the end of the fiscal year 2013.